8 October 2025

Fusion Antibodies plc

("Fusion" or the "Company")

Contract Win

New multi-target Humanisation project with global pharmaceutical company

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has been selected to proceed with a new multi-target Integrated Therapeutic Antibody Services project (the "Project") with the Antibody Centre of Excellence of a European-based global pharmaceutical company (the "Client") under a Master Service Agreement ("MSA") signed earlier in the year. The Project will include humanisation and supply elements.

Humanisation is the process required to make antibodies which were derived from non-human sequences, typically from mouse or rabbit antibodies, suitable for use as human therapeutics. Fusion will humanise a family of VHH antibody fragments for the Client. The Project also involves the expression, purification and supply of research materials.

The selection of Fusion for this Project again demonstrates the Company's ability to secure contracts with major pharmaceutical businesses. This is seen as a significant part of the Company's strategy of reducing dependence on more volatile smaller clients, but also in seeking to exploit the Company's novel technologies such as OptiMAL®. This will hopefully drive sustainable growth, strengthen market positioning and open further new commercial opportunities.

Work in relation to the Project is expected to be completed within the current financial year and the Company expects to generate revenues of not less than £175,000.

Adrian Kinkaid, CEO of Fusion, said: "We are delighted to have been selected to humanise a family of VHH antibody fragments for our Client. It is particularly gratifying that a client of this magnitude and recognised expertise, with all the resources available to them, has selected Fusion to undertake this critical work. It reflects both our position as providers of world-class antibody engineering services and our ability to deliver innovative, high-quality solutions for long-lasting partnerships. We look forward to working with our Client to bring better antibodies to the clinic more rapidly."

Navigate to our Interactive Investor hub here: https://investorhub.fusionantibodies.com/. Engage with us by asking questions, watching video summaries and seeing what other shareholders have to say.

Enquiries: 

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx ^TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 285 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.